Purpose and Summary
H.R. 455 makes technical corrections to the definitions section of the Controlled Substances Act.
house · Committee report
TO AMEND THE CONTROLLED SUBSTANCES ACT TO FIX A TECHNICAL ERROR IN THE DEFINITIONS
2024-09-17
H.R. 455 makes technical corrections to the definitions section of the Controlled Substances Act.
In 2018, the First Step Act (FSA) created two new types of recidivist enhancements, ``serious drug felony'' and ``serious violent felony.''\1\ The FSA included a redundantly numbered subparagraph 57 such that ``serious drug felony'' and ``serious violent felony'' are now misnumbered in statute.\2\ The misnumbering of the affected subparagraphs causes confusion in federal district courts during litigation and can result in costly mistakes when the wrong subparagraph 57 charge is used. Correcting this error is important to the efficiency and accuracy of federal criminal court cases. H.R. 455 rectifies this technical error by correctly renumbering the affected subparagraphs in the statute. --------------------------------------------------------------------------- \1\Public Law 115-391, First Step Act of 2018, Section 401. \2\Public Law 91-513 (as amended by Public Law 117-3280, Controlled Substances Act, Section 102. ---------------------------------------------------------------------------
On June 21, 2023, the Subcommittee on Health held a hearing on several bills, including legislation concerning controlled substances. The title of the hearing was ``Responding to America's Overdose Crisis: An Examination of Legislation to Build Upon the SUPPORT Act.'' The Subcommittee received testimony from: Matthew Strait, Deputy Assistant Administrator, Office of Diversion Control for the Drug Enforcement Administration; Christopher Jones, PharmD, DrPH, MPH, Director of the National Center for Injury Prevention and Control for the Centers for Disease Control and Prevention; Tom Coderre, Acting Deputy Assistant Secretary for Mental Health and Substance Use; Diana Espinosa, MPP, Principal Deputy Administrator of the Health Resources and Services Administration, Acting Deputy Assistant Secretary for Mental Health and Substance Use; and Jonathan Blum, MPP, Principal Deputy Administrator and Chief Operating Officer for the Centers for Medicare and Medicaid Services. On May 16, 2024, the Subcommittee on Health met in open markup session and forwarded H.R. 455, without amendment, to the full Committee by a roll call vote of 24 yeas to 0 nays. On June 4, 2024, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 455, without amendment, favorably reported to the House by a record vote of 44 yeas and 0 nays.
Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held a hearing and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 455 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.
Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to fix a technical error in the definitions section of the Controlled Substances Act. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 455 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, the following related hearing was used to develop or consider H.R. 455: On June 21, 2023, the Subcommittee on Health held a hearing on H.R. 455. The title of the hearing was ``Responding to America's Overdose Crisis: An Examination of Legislation to Build Upon the SUPPORT Act.'' The Subcommittee received testimony from: Matthew Strait, Deputy Assistant Administrator, Office of Diversion Control for the Drug Enforcement Administration; Christopher Jones, PharmD, DrPH, MPH, Director of the National Center for Injury Prevention and Control for the Centers for Disease Control and Prevention; Tom Coderre, Acting Deputy Assistant Secretary for Mental Health and Substance Use; Diana Espinosa, MPP, Principal Deputy Administrator of the Health Resources and Services Administration, Acting Deputy Assistant Secretary for Mental Health and Substance Use; and Jonathan Blum, MPP, Principal Deputy Administrator and Chief Operating Officer for the Centers for Medicare and Medicaid Services. Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmark, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 455 contains no earmarks, limited tax benefits, or limited tariff benefits. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation Section 1. Amendments to the Controlled Substance Act Section 1 redesignates paragraph (58) as (59) and the second paragraph (57) as (58). Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): CONTROLLED SUBSTANCES ACT * * * * * * * TITLE II--CONTROL AND ENFORCEMENT Part A--Short Title; Findings and Declaration; Definitions * * * * * * * definitions Sec. 102. As used in this title: (1) The term ``addict'' means any individual who habitually uses any narcotic drug so as to endanger the public morals, health, safety, or welfare, or who is so far addicted to the use of narcotic drugs as to have lost the power of self-control with reference to his addiction. (2) The term ``administer'' refers to the direct application of a controlled substance to the body of a patient or research subject by-- (A) a practitioner (or, in his presence, by his authorized agent), or (B) the patient or research subject at the direction and in the presence of the practitioner, whether such application be by injection, inhalation, ingestion, or any other means. (3) The term ``agent'' means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser; except that such term does not include a common or contract carrier, public warehouseman, or employee of the carrier or warehouseman, when acting in the usual and lawful course of the carrier's or warehouseman's business. (4) The term ``Drug Enforcement Administration'' means the Drug Enforcement Administration in the Department of Justice. (5) The term ``control'' means to add a drug or other substance, or immediate precursor, to a schedule under part B of this title, whether by transfer from another schedule or otherwise. (6) The term ``controlled substance'' means a drug or other substance, or immediate precursor, included in schedule I, II, III, IV, or V of part B of this title. The term does not include distilled spirits, wine, malt beverages, or tobacco, as those terms are defined or used in subtitle E of the Internal Revenue Code of 1954. (7) The term ``counterfeit substance'' means a controlled substance which, or the container or labeling of which, without authorization, bears the trademark, trade name, or other identifying mark, imprint, number, or device, or any likeness thereof, of a manufacturer, distributor, or dispenser other than the person or persons who in fact manufactured, distributed, or dispensed such substance and which thereby falsely purports or is represented to be the product of, or to have been distributed by, such other manufacturer, distributor, or dispenser. (8) The terms ``deliver'' or ``delivery'' mean the actual, constructive, or attempted transfer of a controlled substance or a listed chemical, whether or not there exists an agency relationship. (9) The term ``depressant or stimulant substance'' means-- (A) a drug which contains any quantity of barbituric acid or any of the salts of barbituric acid; or (B) a drug which contains any quantity of (i) amphetamine or any of its optical isomers; (ii) any salt of amphetamine or any salt of an optical isomer of amphetamine; or (iii) any substance which the Attorney General, after investigation, has found to be, and by regulation designated as, habit forming because of its stimulant effect on the central nervous system; or (C) lysergic acid diethylamide; or (D) any drug which contains any quantity of a substance which the Attorney General, after investigation, has found to have, and by regulation designated as having, a potential for abuse because of its depressant or stimulant effect on the central nervous system or its hallucinogenic effect. (10) The term ``dispense'' means to deliver a controlled substance to an ultimate user or research subject by, or pursuant to the lawful order of, a practitioner, including the prescribing and administering of a controlled substance and the packaging, labeling, or compounding necessary to prepare the substance for such delivery. The term ``dispenser'' means a practitioner who so delivers a controlled substance to an ultimate user or research subject. (11) The term ``distribute'' means to deliver (other than by administering or dispensing) a controlled substance or a listed chemical. The term ``distributor'' means a person who so delivers a controlled substance or a listed chemical. (12) The term ``drug'' has the meaning given that term by section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act. (13) The term ``felony'' means any Federal or State offense classified by applicable Federal or State law as a felony. (14) The term ``isomer'' means the optical isomer, except as used in schedule I(c) and schedule II(a)(4). As used in schedule I(c), the term ``isomer'' means any optical, positional, or geometric isomer. As used in schedule II(a)(4), the term ``isomer'' means any optical or geometric isomer. (15) The term ``manufacture'' means the production, preparation, propagation, compounding, or processing of a drug or other substance, either directly or indirectly or by extraction from substances of natural origin, or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of such substance or labeling or relabeling of its container; except that such term does not include the preparation, compounding, packaging, or labeling of a drug or other substance in conformity with applicable State or local law by a practitioner as an incident to his administration or dispensing of such drug or substance in the course of his professional practice. The term ``manufacturer'' means a person who manufactures a drug or other substance. (16)(A) Subject to subparagraph (B), the terms ``marihuana'' and ``marijuana'' mean all parts of the plant Cannabis sativa L., whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin. (B) The terms ``marihuana'' and ``marijuana'' do not include-- (i) hemp, as defined in section 297A of the Agricultural Marketing Act of 1946; or (ii) the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks (except the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. (17) The term ``narcotic drug'' means any of the following whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (A) Opium, opiates, derivatives of opium and opiates, including their isomers, esters, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation. Such term does not include the isoquinoline alkaloids of opium. (B) Poppy straw and concentrate of poppy straw. (C) Coca leaves, except coca leaves and extracts of coca leaves from which cocaine, ecgonine, and derivatives of ecgonine or their salts have been removed. (D) Cocaine, its salts, optical and geometric isomers, and salts of isomers. (E) Ecgonine, its derivatives, their salts, isomers, and salts of isomers. (F) Any compound, mixture, or preparation which contains any quantity of any of the substances referred to in subparagraphs (A) through (E). (18) The term ``opiate''or ``opioid'' means any drug or other substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction- sustaining liability. (19) The term ``opium poppy'' means the plant of the species Papaver somniferum L., except the seed thereof. (20) The term ``poppy straw'' means all parts, except the seeds, of the opium poppy, after mowing. (21) The term ``practitioner'' means a physician, dentist, veterinarian, scientific investigator, pharmacy, hospital, or other person licensed, registered, or otherwise permitted, by the United States or the jurisdiction in which he practices or does research, to distribute, dispense, conduct research with respect to, administer, or use in teaching or chemical analysis, a controlled substance in the course of professional practice or research. (22) The term ``production'' includes the manufacture, planting, cultivation, growing, or harvesting of a controlled substance. (23) The term ``immediate precursor'' means a substance-- (A) which the Attorney General has found to be and by regulation designated as being the principal compound used, or produced primarily for use, in the manufacture of a controlled substance; (B) which is an immediate chemical intermediary used or likely to be used in the manufacture of such controlled substance; and (C) the control of which is necessary to prevent, curtail, or limit the manufacture of such controlled substance. (24) The term ``Secretary'', unless the context otherwise indicates, means the Secretary of Health and Human Services. (25) The term ``serious bodily injury'' means bodily injury which involves-- (A) a substantial risk of death; (B) protracted and obvious disfigurement; or (C) protracted loss or impairment of the function of a bodily member, or organ, or mental faculty. (26) The term ``State'' means a State of the United States, the District of Columbia, and any commonwealth, territory, or possession of the United States. (27) The term ``ultimate user'' means a person who has lawfully obtained, and who possesses, a controlled substance for his own use or for the use of a member of his household or for an animal owned by him or by a member of his household. (28) The term ``United States'', when used in a geographic sense, means all places and waters, continental or insular, subject to the jurisdiction of the United States. (29) The term ``maintenance treatment'' means the dispensing, for a period in excess of twenty-one days, of a narcotic drug in the treatment of an individual for dependence upon heroin or other morphine-like drugs. (30) The term ``detoxification treatment'' means the dispensing, for a period not in excess of one hundred and eighty days, of a narcotic drug in decreasing doses to an individual in order to alleviate adverse physiological or psychological effects incident to withdrawal from the continuous or sustained use of a narcotic drug and as a method of bringing the individual to a narcotic drug-free state within such period. (31) The term ``Convention on Psychotropic Substances'' means the Convention on Psychotropic Substances signed at Vienna, Austria, on February 21, 1971; and the term ``Single Convention on Narcotic Drugs'' means the Single Convention on Narcotic Drugs signed at New York, New York, on March 30, 1961. (32)(A) Except as provided in subparagraph (C), the term ``controlled substance analogue'' means a substance-- (i) the chemical structure of which is substantially similar to the chemical structure of a controlled substance in schedule I or II; (ii) which has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I or II; or (iii) with respect to a particular person, which such person represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I or II. (B) The designation of gamma butyrolactone or any other chemical as a listed chemical pursuant to paragraph (34) or (35) does not preclude a finding pursuant to subparagraph (A) of this paragraph that the chemical is a controlled substance analogue. (C) Such term does not include-- (i) a controlled substance; (ii) any substance for which there is an approved new drug application; (iii) with respect to a particular person any substance, if an exemption is in effect for investigational use, for that person, under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) to the extent conduct with respect to such substance is pursuant to such exemption; or (iv) any substance to the extent not intended for human consumption before such an exemption takes effect with respect to that substance. (33) The term ``listed chemical'' means any list I chemical or any list II chemical. (34) The term ``list I chemical'' means a chemical specified by regulation to the Attorney General as a chemical that is used in manufacturing a controlled substance in violation of this title and is important to the manufacture of the controlled substances, and such term includes (until otherwise specified by regulation of the Attorney General, as considered appropriate by the Attorney General or upon petition to the Attorney General by any person) the following: (A) Anthranilic acid, its esters, and its salts. (B) Benzyl cyanide. (C) Ephedrine, its salts, optical isomers, and salts of optical isomers. (D) Ergonovine and its salts. (E) Ergotamine and its salts. (F) N-Acetylanthranilic acid, its esters, and its salts. (G) Norpseudoephedrine, its salts, optical isomers, and salts of (H) Phenylacetic acid, its esters, and its salts. (I) Phenylpropanolamine, its salts, optical isomers, and salts of optical isomers. (J) Piperidine and its salts. (K) Pseudoephedrine, its salts, optical isomers, and salts of optical isomers. (L) 3,4-Methylenedioxyphenyl-2-propanone. (M) Methylamine. (N) Ethylamine. (O) Propionic anhydride. (P) Isosafrole. (Q) Safrole. (R) Piperonal. (S) N-Methylephedrine. (T) N-methylpseudoephedrine. (U) Hydriodic acid. (V) Benzaldehyde.
Source: https://api.congress.gov/v3/committee-report/118/hrpt/681